The headline reads as positive (52% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › MRK
Merck & Company, Inc. (MRK) stock analysis
SKIP 3% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Merck & Company, Inc. (MRK) SKIP with 3% confidence at a price of $140.93. That means the signals cancel out; the model sees no clear edge either way.
SectorHealthcare
IndustryDrug Manufacturers - General
Market cap347.70B
Analysed price$140.93
Technical picture
The 14-day RSI is 48, close to the neutral 50 line, so momentum is balanced.
MACD is below its signal line, so short-term momentum is pointing down.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is about normal (0.8x the 20-day average).
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $122.61 and the swing low is $106.50; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The PEG ratio is 2.66, which looks expensive relative to its growth.
The company reports a profit margin of 4.8% and revenue growth of +5.1%.
In its latest quarter it earned $-0.13 per share, which beat the $-0.26 analysts expected, with revenue +5.1% year over year.
Wall Street's average rating is 1.8 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $159.22.
Research notes
Merck’s bull case centers on strong KEYTRUDA oncology performance, positive late-stage data for its Moderna-partnered melanoma vaccine, and growth from newer products such as Winrevair, Welireg, and Capvaxive; Guggenheim reiterated a Buy rating with a $170 target. The bear case is valuation and concentration risk: KEYTRUDA’s U.S. patent expiry around 2028 could bring sharp biosimilar-driven sales declines, while Gardasil sales have weakened and Merck’s elevated earnings multiple leaves less room for execution misses. The major catalyst today was Merck’s third-quarter earnings report, which reportedly beat expectations and prompted the company to raise its 2026 outlook, with KEYTRUDA delivering a notable upside surprise.
The model's one-paragraph read
No clear edge (SKIP) — composite score +0.03 (SKIP). Technicals: RSI 47.94, MACD bearish, price below SMA50. Fundamentals: PEG 2.66, margin 4.8%, revenue growth 5.1%. Financial results: YoY revenue +5.1%, last EPS surprise +50.0%. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bullish order block. FinGPT news read: neutral. Memory: 1 prior look(s). Internet research: Merck’s **bull case** centers on strong KEYTRUDA oncology performance, positive late-stage data for its Moderna-partnered melanoma vaccine, and growth from newer products such as Winrevair, Welireg, and Capvaxive; Guggenheim reiterated a Buy rating with a $170 target. The **bear case** is valuation and concentration risk: KEYTRUDA’s U.S. patent expiry around 2028 could bring sharp biosimilar-driven sales declines, while Gardasil sales have weakened and Merck’s elevated earnings multiple leaves less room for execution misses. The major catalyst today was Merck’s third-quarter earnings report, which reportedly beat expectations and prompted the company to raise its 2026 outlook, with KEYTRUDA delivering a notable upside surprise. Reference price $140.93; no trade levels (SKIP).
Past ratings for MRK
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | SKIP | 3% | $140.93 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on MRK
Oct 29, 2026 · Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
- Oct 29, 2026: Merck shares rise on Q3 beat, raised 2026 profit outlook (Investing.com)
- Oct 29, 2026: Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength (CNBC)
- Oct 29, 2026: Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength (CNBC)
- Oct 29, 2026: Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline (Business Wire)
- Oct 29, 2026: Merck Earnings Blow Past Estimates. Why Wall Street Is Looking Past the Numbers. (Barrons.com)
- Oct 29, 2026: Merck: Q3 Earnings Snapshot (Associated Press)
- Oct 29, 2026: Merck Revenue Up on Keytruda, Winrevair Growth (The Wall Street Journal)
Other Healthcare stocks we cover
NRC · NVO · OSCR · PCRX · PFE · PGNY · PHG · PHR · PRGO · SDZNY · SLS · SNN
Frequently asked questions
Is MRK a buy right now?
As of Oct 29, 2026, our automated model rates Merck & Company, Inc. (MRK) SKIP with 3% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.